FGF2 is also upregulated in prostate cancer and a ribozyme-targeting approach to selectively deplete FGF-binding protein (FGF-BP) to reduce FGF2 mobilization and activation from the ECM has been shown to prevent PC-3 xenograft tumor formation in athymic nude mice [301]. The gene discussed is FGF2; the disease is prostate carcinoma.